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Pneumothorax with a persistent air leak that does not
resolve under prolonged tube thoracostomy suction is
usually treated surgically. However, patients with severe
pulmonary diseases such as progressive pulmonary fibrosis
and chronic pulmonary emphysema are not good candi-
dates for surgical treatment. Chemical pleurodesis with
tetracycline has been reported and accepted as a treatment
for recurrent pneumothorax (1–5). However, it is ineVective
when the lungs of the patients are deflated. Moreover,
chemical pleurodesis with tetracycline has been reported to
induce inflammation and symphysis between the visceral
and parietal pleura. As an alternative method for pleurod-
esis, autologous blood injection into the pleural space has
been reported for the treatment of spontaneous pneumo-
thorax (6,7). These reports described a successful treatment
with autologous blood injection for pneumothorax patients
with or without residual pleural space. The purpose of this
study was to evaluate the eYcacy and safety of autologous
blood-patch pleurodesis for secondary spontaneous pneu-
mothorax with a persistent air leak, including pneumo-
thorax patients whose lungs were not inflated before the
injection of blood.Received 17 November 1998 and accepted 9 February 1999.
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yhasega@tsuru.med.nagoya-u.ac.jpPatients and Methods
This study was undertaken between January 1994 and
January 1997. Eleven patients (10 men and one woman)
were enrolled. Informed consent was obtained from all
patients. They ranged in age from 22 to 83 years. All0954-6111/99/060432+03 $12.00/0patients had a lung with a persistent air leak that had not
resolved under prolonged tube thoracostomy suction for
more than five days. Since one patient had pneumothorax
on the other side, and five patients had recurrent pneumo-
thorax at various intervals, we performed the procedure for
17 occurrences in 11 patients. All patients had underlying
conditions, such as severe lung diseases, with a high surgical
risk (Table 1). Thus they were not good candidates for
thoracotomy. When autologous blood pleurodesis was
undertaken, the lung was inflated in 10 instances but not in
seven by tube thoracostomy suction.
We performed the procedure according to the method
described by Dumire et al. (6). Briefly, autologous blood
(50 ml) without anticoagulant was obtained from each
patient. As soon as the blood was drawn from the patient,
it was immediately injected into the pleural space through a
double-lumen chest tube that attaches to the rubber injec-
tion plug for the administration of drugs. The connected
tube was elevated 60 cm above the patient and left to
water-seal for 2 h. During this period, the patients were
asked to change their position in bed frequently. Thereafter,
suction was reapplied. When the air leak continued for
more than 2 days, we repeated autologous blood infusionsTable 1. Patient characteristics
Patients (n) 11
Age (years)
Median 70
Range 22–83
Sex
Men 10
Women 1
Underlying disease
Emphysema 7
Tuberculosis 2
Lung cancer 1
Histiocytosis X 1? 1999 W. B. SAUNDERS COMPANY LTD
AUTOLOGOUS BLOOD-PATCH PLEURODESIS 433once more. The chest tube was removed 2 days after the air
leak stopped and the lungs were expanded. The patient was
observed for at least 1 week after removing the chest tube.
When the air leak stopped within 2 days of autologous
blood injection, and no recurrence of pneumothorax was
observed for more than 1 week, the procedure was judged
to have been eVective.Results and Discussion
We treated 11 patients for 17 occurrences of pneumothorax
with a persistent air leak. The lungs were inflated in 10 of
those but not inflated in seven under prolonged tube
thoracostomy suction when pleurodesis was performed.
After the final treatment including the initial and the
repeated injection with autologous blood, the persistent air
leak was resolved in 10 instances (59%). Six were from 10
instances of inflated lung (60%), and four were from seven
instances with deflated lungs (57%) (Table 2). There were
no harmful eVects such as fever, nausea or pain. The
follow-up in this study ranged from 2 months to 2 years.
There were two recurrences. One developed after 5 months
and another occurred after 8 days. Repeated autologous
blood-patch pleurodesis was accomplished in both cases,
and the procedure was successful.
Blood-patch pleurodesis has been reported for the treat-
ment of pneumothorax with a persistent pulmonary air
leak. Robinson reported blood pleurodesis in 25 patients
with spontaneous pneumothorax (8). He treated the
patients with blood pleurodesis after the air leak had
stopped and the lung had expanded. He used autologous
blood as one of the sclerosing agents instead of tetracycline
or talc. Autologous blood-patch pleurodesis for a persistent
pulmonary air leak was first reported in two cases by
Dumire et al. (6). The lungs in their patients were
fully inflated. Moreover, Mallen et al. reported that
autologous blood-patch pleurodesis was eVective in one
pneumothorax patient with residual air space (7). Although
the mechanism of autologous blood pleurodesis is not
clear, Dumire et al. assumed that: 1. the blood-patch
eVect, that is, blood coagulation, seals the air leak; and 2.
the actual pleurodesis occurs afterwards by inflammation
and scarring. Therefore, we speculated that autologous
blood-patch pleurodesis would be eVective for patients withresidual air space in pneumothorax or a deflated lung with
a persistent air leak. In fact, we demonstrate in this
study that autologous blood-patch pleurodesis was per-
formed in seven instances of deflated lung, and was
eVective in four (Table 2). However, considering the
initial treatment of autologous blood injection, four of 10
patients (40%) with inflated lungs and only one of seven
patients with deflated lungs were successfully treated. These
findings suggested that the repeated injection would
be required for achieving the autologous blood-patch
pleurodesis.
As for the harmful eVects of autologous blood injection,
we did not observe any adverse eVects such as fever, nausea
or pain in our series. No harmful eVects have been observed
by others (6,7), except for one study which reported pleural
infection only in one patient for an overall incidence of 4%
(8). Pain and fever are major problems to manage under
chemical pleurodesis with tetracycline. As for the auto-
logous blood injection, sedation and antipyresis were not
required during the procedure.
Spontaneous pneumothorax is subclassified as primary
and secondary. Chronic obstructive pulmonary diseases are
the most frequent underlying conditions in secondary spon-
taneous pneumothorax. The initial treatment of secondary
spontaneous pneumothorax is tube thoracostomy. After 7
days of tube thoracostomy drainage, the lung remains
deflated or the air leak persists in about 20% of patients
(9,10). These patients are surgically treated with thora-
cotomy or thoracoscopy under general anaesthesia. How-
ever, those who are of advanced age or have severe
underlying diseases and complications are at risk for gen-
eral anaesthesia or surgical treatment, and an alternative
treatment would be required. The chemical pleurodesis
method with tetracycline is accepted for recurrent pneumo-
thorax (1–5). However, the treatment is thought to be
eVective when the procedure is done after the air leak
has stopped and the lung has expanded. A large-scale
prospective, randomized clinical trial of tetracycline pleuro-
desis by Light et al. (11) has also suggested that teracycline
administration had no eVect on the patients with persistent
air leaks and the closure of bronchopleural fistula. In
contrast to tetracycline, autologous blood pleurodesis
rarely induces severe inflammation and scarring, and the
destruction of the pleura. In addition, the procedure is safe
and eVective for patients with a residual air space in
pneumothorax or with an unexpanded lung with a persist-
ent air leak.
In conclusion, we showed that blood-patch pleurodesis
was eVective in patients with a persistent air leak in
pneumothorax, even if they had an underlying disease with
residual air in the pleural space. This procedure is also
simple and inexpensive. When patients with pneumothorax
have severe underlying pulmonary diseases such as pulmon-
ary fibrosis and chronic pulmonary emphysema and the
tetracycline chemical pleurodesis or surgical treatment was
not appreciated, autologous blood-patch pleurodesis
appears to be worth consideration for the treatment of
pneumothorax with persistent air leak, including pneumo-
thorax patients whose lungs were not inflated before the
injection of blood.Table 2. Results of autologous blood-patch pleurodesis
Inflated lung Deflated lung
Success
(n)
Failure
(n)
Success
(n)
Failure
(n)
Blood injections (n)
1 4 2 1 2
2 2 2 3 1
Total (n) 6 4 4 3
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